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The application of boron neutron capture therapy (BNCT) medi-
ated by liposomes containing 10B-enriched polyhedral borane and
carborane derivatives for the treatment of head and neck cancer in
the hamster cheek pouch oral cancer model is presented. These
liposomes are composed of an equimolar ratio of cholesterol and
1,2-distearoyl-sn-glycero-3-phosphocholine, incorporating K[nido-
7-CH3(CH2)15-7,8-C2B9H11] (MAC) in the bilayer membrane while
encapsulating the hydrophilic species Na3[ae-B20H17NH3] (TAC) in
the aqueous core. Unilamellar liposomes with a mean diameter of
83 nm were administered i.v. in hamsters. After 48 h, the boron
concentration in tumors was 67 ± 16 ppm whereas the precancer-
ous tissue contained 11 ± 6 ppm, and the tumor/normal pouch
tissue boron concentration ratio was 10:1. Neutron irradiation giv-
ing a 5-Gy dose to precancerous tissue (corresponding to 21 Gy in
tumor) resulted in an overall tumor response (OR) of 70% after a
4-wk posttreatment period. In contrast, the beam-only protocol
gave an OR rate of only 28%. Once-repeated BNCT treatment with
readministration of liposomes at an interval of 4, 6, or 8 wk resulted
in OR rates of 70–88%, of which the complete response ranged
from 37% to 52%. Because of the good therapeutic outcome, it
was possible to extend the follow-up of BNCT treatment groups
to 16 wk after the first treatment. No radiotoxicity to normal tissue
was observed. A salient advantage of these liposomes was that
only mild mucositis was observed in dose-limiting precancerous tis-
sue with a sustained tumor response of 70–88%.
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Boron neutron capture therapy (BNCT) is a binary cancertreatment modality that combines irradiation using a thermal
or epithermal neutron beam with 10B target species that are taken
up preferentially by neoplastic cells. The high linear energy
transfer (LET) α-particles and recoiling 7Li nuclei emitted during
the neutron capture reaction have a range of 5–9 μm in tissue
(approximately the diameter of one cell) and are known to have
a high relative biological effectiveness (1). In this way, BNCT will
selectively target tumor tissue while sparing normal tissue. In
addition, because BNCT involves biochemical rather than geo-
metric targeting, it is ideally suited to treat infiltrating tumor cells,
undetectable micrometastases (2), and the foci of malignant
transformation in field-cancerized tissue (3). Clinical trials of
BNCT for the treatment of glioblastoma multiforme and/or
melanoma and, more recently, head and neck tumors and
liver metastases, using boronophenylalanine (BPA) or sodium
mercaptoundecahydrododecaborane as the 10B carriers, have
been performed or are under way in Argentina, Europe, Japan,
Taiwan, and the United States (4–8). These treatments have
been marginally more effective than external-beam radiation
therapy (9–11).
The requirements for successful BNCT are preferential ac-
cumulation and retention of a nontoxic 10B carrier in a tumor,
a sufficiently high absolute concentration of 10B in tumor tissue
(at least 20 ppm) for a sufficient number of 10B(n,α)7Li reactions
to occur, and targeting of all tumor cell populations (12–14).
Furthermore, the microlocalization of 10B also determines the
therapeutic outcome of BNCT (15). To this end, the de-
velopment of new, more selective, nontoxic, and effective boron
delivery agents that can preferentially deliver a high concentra-
tion of boron to the tumor tissue with a high tumor-to-blood
boron ratio is probably the single greatest need for the future
progress of BNCT (16).
Considerable attention has been focused on the liposomal
delivery system as a new targeting modality. Liposomes are ef-
ficient drug delivery vehicles that are able to selectively deliver
large quantities of a wide variety of 10B agents to the tumor
tissue. Small liposomes (<100 nm) pass through aberrant tumor
vessels (17) and passively accumulate by the enhanced perme-
ability and retention effect (18, 19). Small unilamellar lipo-
somes in particular are viewed as potentially useful boron
delivery vehicles for BNCT and have been extensively studied by
Hawthorne and coworkers (20–26) and other groups (27–29). They
can encapsulate aqueous solutions of sodium salts of polyhedral
borane anions and/or incorporate lipophilic boron-containing
moieties embedded within the bilayer membrane. Recently,
Hawthorne and coworkers demonstrated the therapeutic
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efficacy of a boron-rich liposomal system, MAC-TAC liposomes,
incorporating K[nido-7-CH3(CH2)15-7,8-C2B9H11] (MAC) in the
lipid bilayer and a hydrophilic species Na3[ae-B20H17NH3] (TAC)
in the aqueous core, for treating BALB/c mice bearing EMT6
mammary adenocarcinomas (26).
Leveraging on the successful liposome mediated BNCT study
in mice, the aim of the present study was to assess the thera-
peutic efficacy and potential radiotoxicity of BNCT mediated by
MAC-TAC liposomes in the hamster cheek pouch oral cancer
model. Our previous biodistribution studies with this model
using MAC-TAC liposomes showed that tumor boron values
peaked at 67 ppm after 48 h with a very favorable 10:1 tumor/
normal tissue ratio (30). Thus, this protocol was very attractive
for radiobiological study.
We previously proposed and validated the use of the hamster
cheek pouch model of oral cancer for BNCT studies (31, 32).
Although progress has been made in the understanding and
treatment of head and neck malignancies, their management
continues to pose a challenge. Squamous cell carcinoma of the
head and neck region is the sixth most common cause of cancer
deaths worldwide. The relatively poor overall 5-y survival rate for
malignancies of the oral cavity of 60% (33) and the fact that
radical surgery causes large tissue defects poses the need for
more effective and less toxic therapies. These should damage
malignant cells selectively, sparing normal cells. Oral mucositis
limits the radiation dose that can be administered with BNCT to
head and neck and brain tumors (6, 7). It is a frequent, dose-lim-
iting side effect during conventional radiotherapy for advanced
head and neck tumors. Approximately 80% of such patients are
thus affected (34). Despite its incidence and clinical relevance, no
effective way to prevent or treat mucositis is currently available
(35). In addition, the inflammatory process associated with mod-
erate mucositis in field-cancerized tissue could favor tumor de-
velopment from this tissue (3, 36). Within this context, BNCT
protocols that minimize mucositis are more likely to deliver ther-
apeutically useful doses to a tumor without exceeding normal and
precancerous tissue tolerances.
In the hamster cheek pouch tumor model, carcinogenesis pro-
tocols lead to the development of what has been called, globally,
“precancerous tissue” (31), from which tumors arise. Thus, this
mode of tumor induction provides a tumor model surrounded by
precancerous tissue. The possibility of studying precancerous tis-
sue in addition to tumor and normal tissue is clinically relevant in
terms of its role as a potentially dose-limiting tissue.
Results and Discussion
In our previous tumor control studies using other boron targeting
agents, the follow-up period was established as 4 wk after a BNCT
treatment. The treatment protocols assayed in the present study
made it possible, to our awareness for the first time, to prolong the
follow-up period beyond 4 wk posttreatment (after one treatment
of BNCT or after the first treatment in the case of two treat-
ments). No normal tissue radiotoxicity was observed with any of
the protocols. In general, body weight (bw) values oscillated
slightly over the posttreatment period evaluated. It was occasion-
ally necessary to euthanize the animals as a result of decline as
a result of one or more of the following factors, all unrelated to
potential BNCT-induced toxicity: overgrowth of nonresponsive
treated tumors, overgrowth of tumors that develop from pre-
cancerous tissue, and general decline caused by hepatic and di-
gestive disorders caused by the carcinogen dimethyl-1,2-
benzanthracene (DMBA) (37). The animals that were followed
for longer periods frequently developed s.c. mammary adeno-
carcinomas in the abdominal region, conceivably related to treat-
ment with DMBA (38). In those cases, the adenocarcinomas were
surgically excised, enabling follow-up to continue uneventfully.
Four Week Follow-Up. Outcome at 4 wk posttreatment is sum-
marized in Table S1. The data corresponding to later time points
(when it was possible to extend the follow-up period) are pre-
sented separately. In the case of the control group (cancerized,
untreated), only 16% of the tumors underwent a spontaneous
reduction in tumor volume and there were no complete tumor
responses (CRs). The results from initial screening with various
neutron irradiation doses (SI Results, S6) led us to perform
subsequent BNCT treatments at 5 Gy to avoid severe mucositis
to the precancerous tissue. The overall tumor response (OR) was
approximately 70%, of which the CR rate was 33%. Because
treatment at a 5-Gy irradiation dose caused only mild mucositis
in precancerous tissue (a maximum of grade 2), the subsequent
two BNCT treatment studies were performed at 5 Gy per
treatment, which corresponds to a per-treatment irradiation dose
of 21 Gy to the tumor tissue. Repeated BNCT treatments were
performed with 4-, 6-, or 8-wk intervals between each treatment.
This resulted in OR rates of 70%, 79%, and 88%, respectively, of
which the CR rates were 52%, 37%, and 50%, respectively,
higher than with the one-treatment protocol. Mucositis in pre-
cancerous tissue in the two-treatment protocol was mild and did
not exceed grade 2. In the case of the beam-only group, the OR
rate 4 wk posttreatment was only 28%, of which the CR rate was
14%. The difference in OR rates between the beam-only group
and the single-treatment group was statistically significant
(P = 0.0001).
Tumor response at 4 wk posttreatment is summarized in Table
S2, considering stratification for tumor size at the time of irra-
diation (i.e., pretreatment), an issue of clinical relevance (39).
For all protocols, the incidence of CR was higher for the small
tumors than for the medium-sized and large tumors (SI Results, S7),
Table 1. Percentage of tumor response at last time point evaluated for each 5-Gy neutron irradiation to precancerous
tissue
Group/outcome 5 Gy single treatment 5 Gy/4 wk/5 Gy 5 Gy/6 wk/5 Gy 5 Gy/8 wk/5 Gy
Hamsters 25 5 4 5
Tumors 102 27 19 8
Follow-up after first (or single) application, wk 4 10 10 16
Response, %
Partial 37 15 42 50
Complete 33 56 37 38
None 29 30 21 13
Overall 71 70 79 88
Neutron irradiation dose to precancerous tissue quoted in Grays; 5 Gy irradiation dose in precancerous tissue corresponds to 21 Gy in tumor.
Interval between BNCT treatments in weeks in the case of repeat treatment. Most of the control animals were euthanized at 4 wk follow-up
due to tumor overgrowth. Thus, it was not possible to time-match the control group with the repeat BNCT treatment groups with extended
follow-up.
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stressing the importance of initiating treatment promptly after
diagnosis.
Extended Follow-Up. As described earlier, the posttreatment fol-
low-up period for tumor control studies in the hamster cheek
pouch oral cancer model was previously established as 4 wk after
one treatment of BNCT or after the second treatment in the case
of two-treatment protocols (12, 40). For the first time to our
awareness, it was possible to extend the follow-up period to
16 wk in the case of two-treatment protocols, mainly as a result of
good therapeutic outcome, i.e., good tumor control, and reduced
mucositis. Table 1 shows tumor response at the last time point
evaluated for two-treatment protocols as shown in the timeline
in Fig. 1. No statistically significant difference in tumor response
was found between follow-up data corresponding to a one-
BNCT treatment and the two-BNCT treatments. This would
imply that the two treatment protocols sustain an OR rate of 70–
88% over a period of 10–16 wk after the first treatment. This
period constitutes ∼13% of the lifespan of a healthy hamster. If a
direct extrapolation were possible, this period would correspond
to a clinically meaningful period of ∼10 y in a human subject.
Fig. 2 graphically presents tumor response for the most repre-
sentative protocols. Fig. 3 illustrates, using a representative ex-
ample, the macroscopic appearance of a tumor-bearing pouch
before and after treatment.
Regarding the development of novel tumors (i.e., tumors not
present at the end of the carcinogenesis protocol) from pre-
cancerous tissue, 100% of the animals in the control group
exhibited novel tumors at 4 wk follow-up (41). In contrast, 64% of
the hamsters in the one-treatment protocol at 4 wk follow-up
developed novel tumors, whereas approximately 75–80% of the
hamsters in the two-treatment protocol (at the longest follow-up
time in each case) developed novel tumors. This would imply that
the two-treatment protocols sustain a partial inhibitory effect of
BNCT on the development of novel tumors from precancerous
tissue for 10–16 wk.
Although we previously demonstrated the therapeutic success
of BNCT mediated by BPA in the hamster cheek pouch oral
cancer model (12, 32), we undoubtedly face the ongoing chal-
lenge of optimizing this technique by using approaches that
would conceivably also be useful in other experimental models
and, eventually, in a clinical scenario. In the case of head and
neck cancer, a therapeutic strategy will be successful if it achieves
tumor response, minimizes the development of mucositis in the
dose-limiting precancerous tissue surrounding the tumor, and
reduces the development of novel tumors from precancerous
tissue. Within this context, the BNCT treatment protocols me-
diated by MAC-TAC liposomes assayed herein for the first time
in an oral cancer model to our knowledge, induced tumor re-
sponse in ≥70% of the tumors with extremely mild mucositis
(grade 1/2) in precancerous tissue and no normal tissue toxicity.
In addition, these protocols partially inhibited the development
of novel tumors from precancerous tissue. Although effective
tumor control has previously been achieved in this model with
the use of other boron carriers (12, 32), this is the first time of
which we are aware that the combination of good tumor re-
sponse, mild mucositis, and partial inhibition of the development
of novel tumors from precancerous tissue has allowed for a lon-
ger follow-up period beyond the previously established time
period. Repeated BNCT treatment yielded a sustained tumor
response of 70–88% (37–56% CR) and a sustained partial in-
hibitory effect on the development of novel tumors from pre-
cancerous tissue up to 16 wk after the first treatment of BNCT.
Our working hypothesis to test the repeat BNCT treatment was
that this strategy would minimize mucositis in dose-limiting pre-
cancerous tissue. We also sought to choose an interval that would
minimize tumor cell repopulation that is known to jeopardize
therapeutic response. Based on the known fact that mucositis is
a multistage process initiated by mucosal injury and associated
with an increased production of inflammatory cytokines, which
cause direct mucosal damage and initiate positive feedback loops
(42), the interval between treatments would allow the inflam-
matory process to partially subside before the second dose is
delivered, preventing enhancement of mucositis. In terms of
therapeutic efficacy, lengthening overall treatment time in con-
ventional (i.e., low-LET) radiotherapy is known to reduce toxicity
at the expense of reducing tumor control probability (43). How-
ever, in the case of BNCT that involves a combination of low and
high LET radiation components, a repeat treatment would allow
for boron retargeting of cell populations originated in tumor cells
that were refractory to the first application and subsequently
proliferated (3, 40). Within the time frame evaluated (intervals of
4, 6, and 8 wk between applications), the present data do not
reveal statistically significant differences in tumor response at-
tributable to differences in the interval. This gives some flexibility
in selecting the best moment for the second application of BNCT
in patient-tailored therapy (39). Admittedly, some patients may
be in too fragile condition to benefit from a double application
protocol. All three intervals would conceivably preclude en-
hancement of mucositis after the second treatment and similarly
minimize repopulation. It is known that inflammation associated
with mucositis can induce tumor promotion, activating pre-
malignant lesions (36, 44). It is one of the hallmarks of cancer,
acting on any stage of tumorigenesis (45). Within this context, the
fact that BNCT can be delivered without enhancing mucositis is
not only an asset in terms of preventing toxicity but also in terms of
inhibiting the development of novel tumors. The development of
novel tumors in precancerous tissue would model the development
of second primary tumors in field-cancerized oral mucosa (3) and
can thus be considered a parameter that affects medium- and long-
term therapeutic outcome.
Fig. 1. Schematic representation of the timeline of the experimental period
corresponding to the treatment protocols of 5 Gy absorbed dose per appli-
cation to the precancerous tissue.
Fig. 2. Histogram illustrating tumor response (percentage of tumors that
exhibit OR or CR) for each group and follow-up time as indicated.











The fact that MAC-TAC liposomes are not toxic and deliver
a high absolute boron concentration to a tumor (67 ± 16 ppm) with
extremely favorable ratios of tumor relative to dose-limiting pre-
cancerous tissue (∼6:1) and normal tissue (∼10:1) (30) made it an
extremely attractive boron carrier to assess in radiobiological stud-
ies. It was possible to deliver a 5-Gy absorbed neutron radiation
dose to the dose limiting-precancerous tissue (4 Gy to normal
tissue) with an associated absorbed tumor radiation dose of 21
Gy. In addition, because of the high absolute boron content in
tumor tissue, the boron radiation component of the total tumor
dose was 90% (Table 2). This is clearly an asset because it
maximizes the tumor-selective component of the total dose.
We can conclude that, in the hamster cheek pouch oral cancer
model, BNCT mediated by MAC-TAC liposomes can achieve sus-
tained, robust tumor control over a long follow-up period of 16 wk.
At the end of the 16-wk period, tumor growth was observed in only
13% of the tumors, whereas, over a period of only 4 wk in untreated
animals and in animals treated with beam only, 84% and 72% of the
tumors, respectively, continued to grow. This tumor control is as-
sociated with the mildest mucositis in dose-limiting precancerous
tissue, a partial inhibitory effect on the development of novel tumors
from precancerous tissue and no normal tissue toxicity.
Materials and Methods
An abbreviated summary of the methods used is given here. SI Materials and
Methods provides detailed experimental procedures. Also, please refer to
our previously published boron biodistribution study (30) for a detailed
description of MAC-TAC liposome administration protocols.
Tumor Induction. Tumors were induced in the right cheek pouch of young
Syrian hamsters by topical application of the carcinogenDMBA0.5% inmineral
oil twice per week for 12 wk as previously described (40, 46) (SI Materials and
Methods, S1). All animal procedures were conducted in accordance with
protocols approved by the National Atomic Energy Commission Animal Care
and Use Committee.
In Vivo BNCT. A suspension of MAC-TAC liposomes with a mean diameter of
83 nmwas administered i.v. at a dose of 18 mg 10B per kilogram bw (SI Materials
and Methods, S2). The dose and postadministration times used for neutron
irradiation were selected on the basis of a previous study (30). This bio-
distribution study involved ∼25 hamsters each with multiple tumors (total of
68 tumors of varying size). Boron concentration in various tissues such as
blood, tumor, precancerous tissue, normal pouch tissue, spleen, liver, and
kidney were determined at 16 h, 30 h, 48 h, 54 h, and 72 h. Boron concen-
tration in blood and tissue was measured by inductively coupled plasma MS.
On average, after 48 h postinjection of MAC-TAC liposomes, the boron
concentration peaked to 67 ppm in tumor, whereas precancerous tissue
incorporated ∼11 ppm of boron. The tumor-to-normal pouch tissue boron
ratio was 10:1. Table 2 presents a representative example of dose pre-
scription data. Previously reported boron concentration values (30) were
used for dose calculation.
The animals were irradiated 48 h postadministration of MAC-TAC lipo-
somes under i.p. ketamine (140 mg/kg bw)/xylazine (21 mg/kg bw) anes-
thesia at the Reactor Argentino 3 nuclear reactor (47). Physical dosimetry
data has been previously reported (48). The thermal neutron flux was ap-
proximately 7.7 × 109 n·cm−2·s−1 in the center of the irradiation position. The
dose rate of γ-rays in air at the irradiation location was 6.5 ± 0.5 Gy·h−1 (SI
Materials and Methods, S3).
A series of preliminary experiments were performed to establish the
optimum radiation dose range. Forty-eight hours after the administration of
MAC-TAC liposomes, an absorbed radiation dose was given as prescribed for
precancerous tissue. The dose-limiting radiation to precancerous tissue in
oral cancer was expected to range from 3.5 Gy to 7 Gy. Having determined
that 3.5 Gy exhibited no radiation toxicity whereas 6 Gy and 7 Gy exhibited
severe toxicity (SI Results, S6), subsequent experiments were performed at
5 Gy (25 hamsters bearing a total of 102 tumors), which resulted in a total
radiation dose of 21 Gy to the tumor tissue. In addition to these experiments,
a few experiments were done in which a repeat BNCT treatment was ad-
ministered (complete with redosing of liposomes) at an interval of 4, 6, or
8 wk between each treatment. Five hamsters bearing a total of 27 tumors
with a 4-wk interval between treatments, 4 hamsters bearing a total of 19
tumors with a 6-wk interval between treatments, and 6 hamsters bearing
a total of 16 tumors with an 8 wk interval between treatments were
evaluated. Group n (6 hamsters bearing a total of 36 tumors) was treated
once with beam only (i.e., neutron irradiation, fluence matched with 5 Gy
BNCT irradiations, with no prior administration of MAC-TAC liposomes) to
evaluate the effect of the background dose. It was not possible to perform
two treatments with beam only as a result of animal decline because of tumor
overgrowth. An additional group of 12 cancerized, untreated hamsters bear-
ing a total of 77 tumors were followed to assess tumor growth without
treatment. This control group was time-matched with the treated groups.
Follow-Up. To evaluate toxicity, the clinical signs and bw of all animals were
monitored twice perweek. The tumor and precancerous tissue responses were
assessed by visual inspection and tumor volume assay before treatment and at
1, 7, 14, 21, and 28 d posttreatment in keeping with the previously established
follow-up period for tumor control studies in this model (12, 32, 40, 49). When
possible, the animals were followed for longer periods of time (up to 16 wk
from the first treatment). Tumor volume was determined by external caliper
measurement of the three largest orthogonal diameters and expressed in
cubic millimeters (32). Any degree of reduction from initial tumor volume was
considered as partial tumor response (PR) as defined in previous studies (49).
Fig. 3. Representative example of a tumor-bearing pouch pretreatment
(Left) and 14 d posttreatment (Right) with 5 Gy absorbed dose to precancerous
tissue. Tumor 1 (1.3 mm3) and tumor 2 (7 mm3) exhibited CR, whereas tumor 3
(17.9 mm3) exhibited PR, with a reduction in volume to 6.6 mm3. Precancerous
pouch tissue surrounding tumor exhibited grade 1 mucositis before and after
treatment.












Tumor 66.6 ± 16.1 0.9 ± 0.1 0.8 ± 0.2 19 ± 6 1.7 ± 0.2 21 ± 6
Precancerous tissue 11.3 ± 6.2 0.9 ± 0.1 0.8 ± 0.2 3 ± 2 1.7 ± 0.2 5 ± 2




— 0.9 ± 0.1 0.8 ± 0.2 — 1.7 ± 0.2 1.7 ± 0.2
The mean thermal neutron fluence at the irradiation position was 3.9 × 1012 ± 8 × 1011 n cm−2 and the irradiation time ranged from 8 to 9 min. Values are
presented as means ± SD.
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A reduction to ≤50% of the initial tumor volume was named PR0.5. CR was
defined as disappearance of the tumor on visual inspection. OR was defined
as PR plus CR (49). Tumor response was evaluated considering three arbitrary
tumor sizes (small, <10 mm3; medium, 10–100 mm3; and large, >100 mm3)
defined to categorize tumor size at the time of irradiation and evaluate
potential differential response according to size (49). The severity of mucositis
was evaluated semiquantitatively in dose-limiting precancerous tissue as
previously described (3, 50, 51) (SI Materials and Methods, S4). To evaluate
the potential inhibitory effect of the different BNCT protocols on the de-
velopment of novel tumors (i.e., tumors not present at the end of the carci-
nogenesis protocol) from precancerous tissue in this model, we used the
percentage of hamsters with novel tumors in the treated pouch as a repre-
sentative end point (SI Materials and Methods, S5) (3, 41).
Statistical analysis of differences in tumor response was performed by
Fisher exact test. Statistical significance was set at P = 0.05.
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